JP2017522311A5 - - Google Patents

Download PDF

Info

Publication number
JP2017522311A5
JP2017522311A5 JP2017502120A JP2017502120A JP2017522311A5 JP 2017522311 A5 JP2017522311 A5 JP 2017522311A5 JP 2017502120 A JP2017502120 A JP 2017502120A JP 2017502120 A JP2017502120 A JP 2017502120A JP 2017522311 A5 JP2017522311 A5 JP 2017522311A5
Authority
JP
Japan
Prior art keywords
cancer
seq
agent
therapy
tigit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2017502120A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017522311A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/040770 external-priority patent/WO2016011264A1/en
Publication of JP2017522311A publication Critical patent/JP2017522311A/ja
Publication of JP2017522311A5 publication Critical patent/JP2017522311A5/ja
Withdrawn legal-status Critical Current

Links

JP2017502120A 2014-07-16 2015-07-16 Tigit阻害剤及び抗癌剤を使用する癌の治療方法 Withdrawn JP2017522311A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462025394P 2014-07-16 2014-07-16
US62/025,394 2014-07-16
PCT/US2015/040770 WO2016011264A1 (en) 2014-07-16 2015-07-16 Methods of treating cancer using tigit inhibitors and anti-cancer agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020103978A Division JP2020180127A (ja) 2014-07-16 2020-06-16 Tigit阻害剤及び抗癌剤を使用する癌の治療方法

Publications (2)

Publication Number Publication Date
JP2017522311A JP2017522311A (ja) 2017-08-10
JP2017522311A5 true JP2017522311A5 (cg-RX-API-DMAC10.html) 2018-08-30

Family

ID=55079055

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017502120A Withdrawn JP2017522311A (ja) 2014-07-16 2015-07-16 Tigit阻害剤及び抗癌剤を使用する癌の治療方法
JP2020103978A Pending JP2020180127A (ja) 2014-07-16 2020-06-16 Tigit阻害剤及び抗癌剤を使用する癌の治療方法
JP2021198263A Withdrawn JP2022046494A (ja) 2014-07-16 2021-12-07 Tigit阻害剤及び抗癌剤を使用する癌の治療方法
JP2024026145A Pending JP2024075568A (ja) 2014-07-16 2024-02-26 Tigit阻害剤及び抗癌剤を使用する癌の治療方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020103978A Pending JP2020180127A (ja) 2014-07-16 2020-06-16 Tigit阻害剤及び抗癌剤を使用する癌の治療方法
JP2021198263A Withdrawn JP2022046494A (ja) 2014-07-16 2021-12-07 Tigit阻害剤及び抗癌剤を使用する癌の治療方法
JP2024026145A Pending JP2024075568A (ja) 2014-07-16 2024-02-26 Tigit阻害剤及び抗癌剤を使用する癌の治療方法

Country Status (19)

Country Link
US (9) US20170143825A1 (cg-RX-API-DMAC10.html)
EP (1) EP3169363A4 (cg-RX-API-DMAC10.html)
JP (4) JP2017522311A (cg-RX-API-DMAC10.html)
KR (1) KR20170023081A (cg-RX-API-DMAC10.html)
CN (1) CN107073108A (cg-RX-API-DMAC10.html)
AU (1) AU2015289621A1 (cg-RX-API-DMAC10.html)
BR (1) BR112017000703A2 (cg-RX-API-DMAC10.html)
CA (1) CA2953245A1 (cg-RX-API-DMAC10.html)
CL (1) CL2017000080A1 (cg-RX-API-DMAC10.html)
CO (1) CO2017001493A2 (cg-RX-API-DMAC10.html)
CR (1) CR20170014A (cg-RX-API-DMAC10.html)
EA (1) EA201790195A1 (cg-RX-API-DMAC10.html)
IL (1) IL249658A0 (cg-RX-API-DMAC10.html)
MA (1) MA40437A (cg-RX-API-DMAC10.html)
MX (1) MX2016017288A (cg-RX-API-DMAC10.html)
PE (1) PE20170140A1 (cg-RX-API-DMAC10.html)
PH (1) PH12017500070A1 (cg-RX-API-DMAC10.html)
SG (2) SG11201700258VA (cg-RX-API-DMAC10.html)
WO (1) WO2016011264A1 (cg-RX-API-DMAC10.html)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2277532A1 (en) 2002-09-11 2011-01-26 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
WO2009126688A2 (en) 2008-04-09 2009-10-15 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
TWI583699B (zh) 2011-09-23 2017-05-21 安可美德藥物股份有限公司 Vegf/dll4結合劑類及彼等之用途
TWI888366B (zh) 2013-07-16 2025-07-01 美商建南德克公司 利用pd-1軸結合拮抗劑及tigit抑制劑治療癌症之方法
CA2957722C (en) 2014-08-19 2022-05-31 Merck Sharp & Dohme Corp. Anti-tigit antibodies
AR103268A1 (es) 2014-12-23 2017-04-26 Bristol Myers Squibb Co Anticuerpos contra tigit
IL254039B2 (en) 2015-02-19 2023-12-01 Compugen Ltd Anti-pvrig antibodies and methods of use
SMT202100467T1 (it) 2015-04-17 2021-09-14 Alpine Immune Sciences Inc Proteine immunomodulatorie con affinità regolabili
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Tigit結合劑和彼之用途
US11371066B2 (en) 2015-07-13 2022-06-28 Modular Genetics, Inc. Generation of acyl alcohols
CN115925931A (zh) 2015-08-14 2023-04-07 默沙东公司 抗tigit抗体
US11339213B2 (en) 2015-09-23 2022-05-24 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
SG10202007764TA (en) 2015-09-25 2020-09-29 Genentech Inc Anti-tigit antibodies and methods of use
MX2018010485A (es) * 2016-03-04 2019-01-10 Jn Biosciences Llc Anticuerpos para inmunoreceptor de celulas t con dominios de ig e itim (tigit).
AU2017248830B2 (en) 2016-04-15 2023-03-09 Alpine Immune Sciences, Inc. CD80 variant immunomodulatory proteins and uses thereof
WO2018022945A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd112 variant immunomodulatory proteins and uses thereof
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
EP3491013A1 (en) 2016-07-28 2019-06-05 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
KR102585976B1 (ko) 2016-08-17 2023-10-05 컴퓨젠 엘티디. 항-tigit 항체, 항-pvrig 항체 및 이들의 조합
MX2019006072A (es) * 2016-11-30 2019-08-14 Oncomed Pharm Inc Metodos para tratamiento de cancer que comprenden agentes de enlace al inmunoreceptor de celulas t con dominios ige itim (tigit).
WO2018102746A1 (en) * 2016-12-02 2018-06-07 Rigel Pharmaceuticals, Inc. Antigen binding molecules to tigit
EP3600357A4 (en) 2017-03-31 2021-01-06 The Board of Trustees of the Leland Stanford Junior University METHODS OF TREATING T-LYMPHOCYTE DEPLETION BY INHIBITING OR MODULATING T-LYMPHOCYTE RECEPTOR SIGNALING
LT3618863T (lt) 2017-05-01 2023-10-10 Agenus Inc. Anti-tigit antikūnai ir jų panaudojimo būdai
JP7348072B2 (ja) 2017-06-01 2023-09-20 コンピュジェン リミテッド 三重併用抗体療法
WO2018229163A1 (en) 2017-06-14 2018-12-20 King's College London Methods of activating v delta 2 negative gamma delta t cells
IL272227B2 (en) 2017-07-27 2025-09-01 iTeos Belgium SA Anti-tigit antibodies
EP3694870A1 (en) 2017-10-10 2020-08-19 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
TWI877769B (zh) * 2017-12-30 2025-03-21 英屬開曼群島商百濟神州有限公司 抗tigit抗體及其作為治療和診斷的用途
SG11202006148UA (en) 2018-01-03 2020-07-29 Alpine Immune Sciences Inc Multi-domain immunomodulatory proteins and methods of use thereof
JP7316284B2 (ja) * 2018-01-15 2023-07-27 ナンジン レジェンド バイオテック カンパニー,リミテッド Tigitに対する抗体及びその多様体
SG11202004521QA (en) 2018-02-06 2020-06-29 I Mab Biopharma Us Ltd Antibodies to t cell immunoreceptor with ig and itim domains (tigit) and uses thereof
US20190247560A1 (en) 2018-02-13 2019-08-15 Gambro Lundia Ab Extracorporeal devices and methods of treating complement factor related diseases
CN112020516B (zh) 2018-03-13 2025-01-03 塔斯克疗法有限公司 用于肿瘤特异性细胞清除的抗-cd25
KR102825164B1 (ko) 2018-03-27 2025-06-26 브리스톨-마이어스 스큅 컴퍼니 자외선 신호를 사용한 단백질 농도의 실시간 모니터링
CA3097593A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
CA3097625A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof
JP7072715B2 (ja) 2018-07-20 2022-05-20 サーフィス オンコロジー インコーポレイテッド 抗cd112r組成物及び方法
EP3841123A2 (en) 2018-08-23 2021-06-30 Seagen Inc. Anti-tigit antibodies
KR102884523B1 (ko) 2018-10-03 2025-11-10 젠코어 인코포레이티드 IL-12 이종이량체 Fc-융합 단백질
CA3116188A1 (en) 2018-10-12 2020-04-16 Xencor, Inc. Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
US11618776B2 (en) 2018-12-20 2023-04-04 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domains
WO2020172658A1 (en) 2019-02-24 2020-08-27 Bristol-Myers Squibb Company Methods of isolating a protein
CN113710706A (zh) * 2019-02-27 2021-11-26 豪夫迈·罗氏有限公司 用于抗tigit抗体和抗cd20抗体或抗cd38抗体治疗的给药
JP2022525928A (ja) * 2019-03-21 2022-05-20 ガミダ セル リミテッド 併用療法における移植に適したnk細胞画分の増殖及び増殖nk細胞画分の使用
KR20220012292A (ko) 2019-05-23 2022-02-03 브리스톨-마이어스 스큅 컴퍼니 세포 배양 배지를 모니터링하는 방법
TWI760751B (zh) 2019-05-29 2022-04-11 美商美國禮來大藥廠 Tigit及pd-1/tigit-結合分子
CN112300279A (zh) * 2019-07-26 2021-02-02 上海复宏汉霖生物技术股份有限公司 针对抗cd73抗体和变体的方法和组合物
EP4037700A2 (en) 2019-10-03 2022-08-10 Xencor, Inc. Targeted il-12 heterodimeric fc-fusion proteins
TW202128757A (zh) 2019-10-11 2021-08-01 美商建南德克公司 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
CN114728171A (zh) 2019-11-05 2022-07-08 默克专利有限公司 抗tigit抗体及其应用
WO2021113831A1 (en) 2019-12-05 2021-06-10 Compugen Ltd. Anti-pvrig and anti-tigit antibodies for enhanced nk-cell based tumor killing
CN112409450B (zh) * 2020-03-29 2023-01-24 郑州大学 TIGIT-IgV的亲和剂及其应用
US12202882B2 (en) 2020-05-08 2025-01-21 Alpine Immune Sciences, Inc. APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof
CN111995681B (zh) * 2020-05-09 2022-03-08 华博生物医药技术(上海)有限公司 抗tigit的抗体、其制备方法和应用
TW202210514A (zh) 2020-06-02 2022-03-16 美商阿克思生物科學有限公司 針對tigit的抗體
WO2021257124A1 (en) 2020-06-18 2021-12-23 Genentech, Inc. Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
TW202216778A (zh) 2020-07-15 2022-05-01 美商安進公司 Tigit及cd112r阻斷
JP2023544410A (ja) 2020-10-05 2023-10-23 ブリストル-マイヤーズ スクイブ カンパニー タンパク質を濃縮するための方法
TW202222345A (zh) * 2020-11-26 2022-06-16 大陸商信達生物製藥(蘇州)有限公司 包含抗tigit/pd-1雙特異性抗體的製劑及其製備方法和用途
CA3217279A1 (en) 2021-05-04 2022-11-10 Olga Ignatovich Anti-tigit antibodies and methods of use thereof
AR125753A1 (es) 2021-05-04 2023-08-09 Agenus Inc Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos
CN118871463A (zh) 2021-07-28 2024-10-29 基因泰克公司 用于治疗癌症的方法和组合物
WO2023056403A1 (en) 2021-09-30 2023-04-06 Genentech, Inc. Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
CN114149489B (zh) * 2021-11-18 2023-12-15 厦门大学 一种靶向tigit的放射性标记化合物及其制备方法和应用
KR20240156411A (ko) 2022-03-09 2024-10-29 브리스톨-마이어스 스큅 컴퍼니 치료 단백질의 일시적 발현
CN119031933B (zh) * 2022-04-12 2025-08-26 正大天晴(广州)医药有限公司 蛋白酶体抑制剂与抗pd-1抗体的药物组合
JP2025523387A (ja) 2022-06-07 2025-07-23 ジェネンテック, インコーポレイテッド 抗pd-l1アンタゴニストおよび抗tigitアンタゴニスト抗体を含む、肺がん治療の有効性を判定するための方法
US20260217828A1 (en) 2023-01-31 2026-07-30 University Of Rochester Immune checkpoint blockade therapy for treating staphylococcus aureus infections
KR20250163916A (ko) 2023-03-06 2025-11-21 제넨테크, 인크. 비소세포 폐암의 예후 및 치료 방법
WO2025174933A1 (en) 2024-02-14 2025-08-21 Genentech, Inc. Methods for treatment of pancreatic cancer with anti-pd-l1 ab, anti-tigit ab, gemcitabine and nab-placlitaxel

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009012343A (es) * 2007-05-14 2010-02-10 Biogen Idec Inc Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello.
WO2009126688A2 (en) * 2008-04-09 2009-10-15 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
SMT201900242T1 (it) * 2012-12-03 2019-05-10 Bristol Myers Squibb Co Incremento dell'attivita' anti-cancro di proteine di fuzione a fc immunomodulatrici
WO2014089169A2 (en) * 2012-12-04 2014-06-12 Oncomed Pharmaceuticals, Inc. Immunotherapy with binding agents

Similar Documents

Publication Publication Date Title
JP7313493B2 (ja) Pd-1阻害剤を投与することによって皮膚がんを処置する方法
ES2944962T3 (es) Métodos de diagnóstico para tratamiento con linfocitos T
JP7324710B2 (ja) 肺癌の処置のための抗pd-1抗体
AU2016268864B2 (en) Methods of conditioning patients for T cell therapy
Vacchelli et al. Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy
JP2022046494A (ja) Tigit阻害剤及び抗癌剤を使用する癌の治療方法
JP2020534250A5 (cg-RX-API-DMAC10.html)
JP2018522887A (ja) 免疫チェックポイント阻害剤を使用する癌の処置法
JP2016528195A5 (cg-RX-API-DMAC10.html)
CN106413751A (zh) 用于治疗癌症的抗ccr4抗体和4‑1bb激动剂的组合
US20190336496A1 (en) Selective bcl-2 inhibitors in combination with an anti-pd-1 or an anti-pd-l1 antibody for the treatment of cancers
JP2024016200A (ja) キメラ抗原受容体療法のt細胞の増殖動態及びその使用
CN111615518B (zh) 阻断emt途径并克服癌干细胞的il8
JP2018518465A5 (cg-RX-API-DMAC10.html)
TWI828626B (zh) 併用包含溶血性鏈球菌之菌體的製劑的療法
JP2021500320A (ja) 癌の治療のための配合剤
Cytryn et al. Biomarker Analysis From a Phase II Study of AgenT-797 (invariant natural killer T cells) with Botensilimab (Fc-enhanced CTLA-4 inhibitor) and Balstilimab (anti-PD-1) in PD-1 Refractory Gastroesophageal Cancer
ES2891990T3 (es) Anticuerpo que se une específicamente a ERBB3 y su uso
CN114616245B (zh) 一种抗cd38的抗体及其用途
Thakur et al. In vitro synthesis of primary specific anti-breast cancer antibodies by normal human peripheral blood mononuclear cells
Vishwakarma et al. Novel Immunotherapeutic Approaches for Cancer Therapy
RU2771759C2 (ru) Антитела против pd-1 для лечения рака легких
Call et al. 1028TiP ARC-12: Phase I/Ib dose escalation and dose expansion study to evaluate the safety and tolerability of AB308+ zimberelimab (AB122) in advanced malignancies
CN116194142A (zh) 通过施用pd-1抑制剂治疗癌症疼痛的方法
Kiakou et al. Cancer immunotherapy: A different approach to the treatment of neoplastic disease.